Mandate

Vinge has advised Ambea on a rights issue

Vinge has advised Ambea AB (publ) on a fully subscribed rights issue, which will provide Ambea with issue proceeds amounting to approximately SEK 1,215 million before costs.

The new shares are expected to be admitted to trading on Nasdaq Stockholm on 25 June 2019.

Ambea is the market leading private care provider in Sweden, Norway and Denmark respectively, with about 900 units and around 26,000 employees. Through the brands Nytida, Vardaga, Lära, Klara, Stendi and Altiden, Ambea provides housing, support, education and personnel for health and social care.

Ambea is listed on Nasdaq Stockholm, Mid cap.

Vinge’s team consisted primarily of Charlotte Levin, Nils Fredrik Dehlin, Annika Nyberg Ekenberg and Marcus Gustavsson.
 

Related

Vinge has advised Eleda in connection with Eleda Norge AS’s acquisition of Nettpartner Bane AS

Vinge, together with Advokatfirmaet Thommessen, has advised Eleda in connection with Eleda Norge AS’s acquisition of Nettpartner Bane AS from Å Energi owned Nettpartner AS.
January 19, 2026

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.
January 14, 2026

Vinge advises Revivo Group on acquisition of Haapanen

Revivo Group, a comprehensive provider of qualified surface treatment services, has acquired Haapanen, a well-established Finnish specialist company.
January 14, 2026